NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Assembly Biosciences, Inc. (ASMB) Stock Analysis

Assembly Biosciences, Inc. (ASMB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ASMB

$36.60

+$0.47 (+1.30%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ASMB with… →

ASMB Key Statistics

As of Sep 4, 2026
Trading
Open
$35.68
Previous Close
$36.13
Day's Range
35.49–36.77
52-Week Range
20.23–39.71
Volume
156.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.13
Valuation
Market Cap
$745.20M
P/E Ratio
29.28
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
9.96
EPS (ttm)Profit attributable to each share over the last twelve months.
1.25
Financials (FY)
Revenue (FY)
$72.30M+153.52%
Net Income (FY)
−$6.12M
Profit marginThe share of revenue left as profit after all costs and taxes.
−0.06%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
20.36M
1-Year Return
+57.01%
Dividend and dates
Avg Volume
238.94K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ASMB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+7.62%
2025+115.53%
2024+60.37%
2023−36.92%
2022−44.21%
2021−61.49%
2020−70.43%
2019−9.55%
2018−50.01%
2017+272.43%
2016 (partial year)+107.34%

As of September 4, 2026.

ASMB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$72.30M−$6.12M−8.5%
2024$28.52M−$40.18M−140.9%
2023$7.16M−$61.23M−854.8%
2022$0.00−$93.09M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$72.30M—−$12.12M−$6.12M−8.5%
2024$28.52M—−$45.42M−$40.18M−140.9%
2023$7.16M—−$64.65M−$61.23M−854.8%
2022$0.00—−$94.11M−$93.09M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ASMB Valuation vs Biotechnology Median

Median of 656 stocks
MetricASMBBiotechnology medianvs median
P/E29.2812.57133% above
P/S ratio9.9615.2635% below
Profit margin−0.06%0.00%0.1 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Assembly Biosciences, Inc. (ASMB) is capitalised at $745.20M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 73.

Over the past 52 weeks the price has ranged from $20.23 to $39.71. The most recent close on file for ASMB is $36.60, dated September 4, 2026. That is +$0.47 (+1.30%) against the previous close. The latest close sits 80.92% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $72.30M. Against the prior fiscal year total of $28.52M, that is a change of +153.52%. The same year closed with a net loss of $6.12M. The reported profit margin is −0.06%. That is 0.1 percentage points below the Biotechnology median of 0%. Trailing earnings per share are 1.25.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $72.30M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 29.28. That is 132.94% above the Biotechnology median of 12.57. The price-to-sales ratio is 9.96. On price-to-sales that is 34.77% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned +57.01%. Measured over 10 years, that is −6.74% a year compounded. Beta against the wider market is reported at 1.13. Daily returns over the trailing 10 years annualize to a volatility of 71.1%.

Growth & Income

No dividend is on file for ASMB.

So far in 2026 the price is +7.62%. Across the complete calendar years on file, 2017 returned +272.43% and 2020 returned −70.43%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Assembly Biosciences, Inc. (ASMB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Assembly Biosciences, Inc. ASMB $745.20M 29.3
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Assembly Biosciences, Inc. trades at a P/E of 29.3.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Assembly Biosciences, Inc.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Visit website →